SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is drawing attention after a cybersecurity-sector rally tied to headlines about AI-discovered vulnerabilities and a critical PHP flaw, which traders say could heighten demand for security products. Some see the move as evidence of strong sector momentum, while others question whether the rally is justified given CRWDs lofty valuation.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced 2026 outlook, and suspended dividend to prioritize debt reduction have driven heavy selling; management attributed the slump to recession-level appliance demand and the Iran war. Traders are debating whether the decline reflects a temporary demand shock or deeper problems with the companys debt, execution, and management, while some see the selloff as a contrarian buying opportunity.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

ESMO updates on RASONQUE and RAS-targeted combinations are driving discussion, including reported survival benefits across patient subgroups and promising pancreatic-cancer data from Tangos combination with daraxonrasib. Traders are debating whether delays among rival programs could extend Revolution Medicines lead, while weighing the competitive landscape and how the clinical findings translate into durable benefit.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Toshibas plan to expand hard-drive capacity has raised fears that added competition could weaken Seagates pricing power, prompting sharp swings in STX alongside Western Digital. Traders are divided: some see a lasting threat to the storage-scarcity thesis, while others view the selloff as an overreaction given the long ramp-up and strong AI data-center demand.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

ARKK is drawing attention for a tentative rebound and attempts to break out of a prolonged, volatile base, with bullish traders pointing to improving momentum and renewed interest in growth stocks. Others remain skeptical, citing the funds past underperformance and Cathie Woods portfolio decisions.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing attention amid a volatile crypto-market pullback, with traders focused on whether it can hold technical support after selloffs and leveraged-position liquidations. Sentiment is split between calls for further downside and dip buyers anticipating a reversal or short squeeze.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is drawing attention amid a broader market pullback, with traders debating whether weakness tied to inflation, elevated yields and geopolitical oil risks could deepen or prove temporary. Bearish crash warnings contrast with dip-buying and long-term investors who view index declines as accumulation opportunities.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics early Phase 1 azer-cel results in progressive MS are drawing attention, with traders highlighting encouraging safety findings and disability scores that were stable or improved in most evaluable patients. Reaction is bullish about the potential to add a pipeline asset beyond BRIUMVI, but some note the small, preliminary study and muted share response, while looking to BRIUMVI sales and upcoming subcutaneous data for further validation.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods upcoming Q3 earnings report is the dominant focus, with traders debating whether event-contract revenue can offset weaker crypto activity and slower growth. Optimism about a strong report competes with concern over the sharp selloff, insider-sale speculation, and sensitivity to crypto and broader market weakness.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs earnings have sparked debate after shares sold off despite improving profitability and cash flow: bulls view the reaction as excessive and cite the companys cash, buybacks and low valuation, while bears focus on declining revenue and weak Chinese consumer demand. The discussion also reflects persistent caution toward Chinese equities and uncertainty over whether JD can turn better margins into renewed growth.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?

Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat 

Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential. 

Healthcare ETFs to Buy as UnitedHealth Beats on Q3 Earnings

UnitedHealth's Q3 earnings beat estimates, lifting shares 6.3%. Explore three healthcare ETFs offering UNH exposure while diversifying Medicaid risks. 

Bet on These Healthcare ETFs to Benefit From the Aging US Population

With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB

Key PointsThe Vanguard Health Care ETF offers a broad healthcare focus with a significantly lower expense ratio of 0.09% compared to its peer...

Consumer Sentiment Drops in September: ETFs to Consider

Consumer sentiment falls to a four-month low amid persistent inflation and uncertainty. Here are some ETFs that investors may consider.

MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near

Equity

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.


Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ?

Key PointsThe Vanguard Health Care ETF (VHT) is significantly cheaper to own than the iShares Global Healthcare ETF (IXJ...

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

Key PointsVanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF...

Vanguard World Fund - Vanguard Health Care ETF

Bearish Sentiment

<ul class="summary-bullets"><li>MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa.&nbsp;</li><li>By late November, the FDA should say whether it accepted the filing, whether it will review it faster, and when it will decide.</li><li>Three shots are already approved for HS: AbbVie’s Humira, Novartis’s Cosentyx, and UCB’s Bimzelx.</li></ul><p>Shares of MoonLake Immunotherapeutics (MLTX) slid about 15% this week as investors marked down the stock weeks before a planned U.S. filing for its lead drug.</p><p>MLTX &nbsp;has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock about 80% below its 52-week high. The stock is on track to clock its worst week in about a year, if losses hold.</p><h2 class="st-heading-2">Filing Date Looms</h2><p>MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa, a painful condition that causes boils and tunnels under the skin. The request would cover both adults and teens. The agency has already said the existing studies can support a filing.</p><p>By late November, the FDA should say whether it accepted the file, whether it will review it faster, and when it will decide. A standard review would point to a possible U.S. launch in the second half of 2027.</p><h2 class="st-heading-2">What The Drug Did In Trials</h2><p>Sonelokimab is an experimental injection that blocks two proteins that drive inflammation. After one year in two late-stage studies, about two-thirds of adults had a large drop in skin lesions and about one-third saw their lesions disappear. Early data in teens looked similar. Safety matched earlier studies.</p><p>Doubt remains because the first look at the data, at four months, was mixed. One study succeeded. The second missed its main goal after patients on dummy treatment improved more than expected, a setback that crushed the stock a year ago. The FDA, however, later said MoonLake did not need new skin-disease trials.</p><p>In August, a late-stage study of the drug in patients with psoriatic arthritis also hit its main goal.</p><h2 class="st-heading-2">A Crowded Market</h2><p>Three shots are already approved for HS: AbbVie’s Humira, Novartis’s Cosentyx, and UCB’s Bimzelx. Other new drugs are also in development.</p><p>MoonLake says its drug design and long-term trial results can help it stand out, but it would enter a market where rivals already have years of real-world use.</p><h2 class="st-heading-2">Next Catalysts</h2><p>MoonLake ended June with $537 million in cash, enough, it says, to last into mid-2028. It has no approved product and lost $131.5 million in the first half of 2026.</p><p>The nearest catalyst for the stock is the hidradenitis filing. A second late-stage joint-disease study should finish enrolling this quarter, with results later this year. MoonLake also plans to start a late-stage trial in palmoplantar pustulosis, which has no approved U.S. treatment.</p><h2 class="st-heading-2">How Did MLTX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around MLTX stock stayed ‘neutral’ over the past 24 hours, while message volume was ‘high.’</p><p>A Stocktwits user said that shorts are resorting to bashing the company for its perceived lack of announcements, as they have no arguments against its drug.</p><p><stembedurl>https://stocktwits.com/Modern_portholio_theory/message/664081954</stembedurl></p><p>Another user opined that even with approval for sonelokimab, the company will enter a crowded market. “Yes the pie is big but it will &nbsp;be divided into many little pieces. $20 is already a lot for this company,” they wrote.</p><p><stembedurl>https://stocktwits.com/Antocar/message/664076232</stembedurl></p><p>Certain analysts, however, are more bullish. Last month, H.C. Wainwright raised the firm's price target on MoonLake Immunotherapeutics to $50 from $45 and kept a Buy rating on the shares after increasing its probabilities of approval to 70% from 60% in hidradenitis suppurativa, to 60% from 50% in psoriatic arthritis, and to 50% from 40% in axial spondyloarthritis.</p><p><a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has fallen 3% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dell-hpe-stocks-lead-s-and-p-500-gains-oracle-s-95-b-capex-plan-lifts-ai-stocks/cZtXFJxRBb2">DELL, HPE Stocks Lead S&amp;P 500 Gains: Oracle’s $95B Capex Plan Lifts AI Stocks</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.

MoonLake Immunotherapeutics

T Rowe Price Capital Appreciation Equity ETF

Vanguard Health Care ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

About VHT